Preparation and evaluation of palmitic acid-conjugated exendin-4 with delayed absorption and prolonged circulation for longer hypoglycemia

International Journal of Pharmaceutics

Volumn 424, Issue 1-2, 2012, Pages 50-57

  Lee, Juho ^a   Lee, Changkyu ^b   Kim, Insoo ^a,b   Moon, Hyung Ryong ^a   Kim, Tae Hyung ^b   Oh, Kyung Taek ^c   Lee, Eun Seong ^d   Lee, Kang Choon ^b   Youn, Yu Seok ^b  

^a Pusan National University   (South Korea)

^b Sungkyunkwan University   (South Korea)

^c Chung Ang University   (South Korea)

^d The Catholic University of Korea   (South Korea)

Author keywords

Albumin binding; Exendin 4; Hypoglycemia; Palmitic acid; Type 2 diabetes

Indexed keywords

EXENDIN 4; GLUCOSE; PALMITIC ACID;

ANIMAL EXPERIMENT; ANTIDIABETIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CHEMICAL MODIFICATION; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DIET RESTRICTION; DRUG ABSORPTION; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG SYNTHESIS; DRUG TISSUE LEVEL; GLUCOSE BLOOD LEVEL; MALE; MAXIMUM PLASMA CONCENTRATION; MICELLIZATION; MOUSE; NEAR INFRARED SPECTROSCOPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PARTICLE SIZE; PLASMA CLEARANCE; PRIORITY JOURNAL; PROTEIN BINDING; TIME TO MAXIMUM PLASMA CONCENTRATION;

ABSORPTION; ANIMALS; BLOOD GLUCOSE; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS; DIABETES MELLITUS, EXPERIMENTAL; FASTING; HALF-LIFE; HYPOGLYCEMIC AGENTS; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED ICR; MICELLES; PALMITIC ACID; PARTICLE SIZE; PEPTIDES; SERUM ALBUMIN; TISSUE DISTRIBUTION; VENOMS;

EID: 84862809661     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2011.12.050     Document Type: Article

References (28)

1. L.L. Baggio, Q. Huang, T.J. Brown, and D.J. Drucker A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis Diabetes 53 2004 2492 2500 (Pubitemid 39145610)
2. L.L. Baggio, Q. Huang, X. Cao, and D.J. Drucker An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis Gastroenterology 134 2008 1137 1147 (Pubitemid 351451971)
3. P. Caliceti, and F.M. Veronese Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates Adv. Drug Deliv. Rev. 55 2003 1261 1277 (Pubitemid 37464561)
4. S.Y. Chae, Y.G. Choi, S. Son, S.Y. Jung, D.S. Lee, and K.C. Lee The fatty acid conjugated exendin-4 analogs for type 2 antidiabetic therapeutics J. Control. Release 144 2010 10 16
5. S.Y. Chae, Y.G. Chun, S. Lee, C.H. Jin, E.S. Lee, K.C. Lee, and Y.S. Youn Pharmacokinetic and pharmacodynamic evaluation of site-specific PEGylated glucagon-like peptide-1 analogs as flexible postprandial-glucose controllers J. Pharm. Sci. 98 2009 1556 1567
6. S.Y. Chae, C.H. Jin, J.H. Shin, S. Son, T.H. Kim, S. Lee, Y.S. Youn, Y. Byun, M.S. Lee, and K.C. Lee Biochemical, pharmaceutical and therapeutic properties of long-acting lithocholic acid derivatized exendin-4 analogs J. Control. Release 142 2010 206 213
7. V.T. Chuang, U. Kragh-Hansen, and M. Otagiri Pharmaceutical strategies utilizing recombinant human serum albumin Pharm. Res. 19 2002 569 577 (Pubitemid 34553662)
8. M.B. Davidson, G. Bate, and P. Kirkpatrick Exenatide Nat. Rev. Drug Discov. 4 2005 713 714
9. C.F. Deacon Therapeutic strategies based on glucagon-like peptide 1 Diabetes 53 2004 2181 2189 (Pubitemid 39145569)
10. C.M. Edwards, S.A. Stanley, R. Davis, A.E. Brynes, G.S. Frost, L.J. Seal, M.A. Ghatei, and S.R. Bloom Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers Am. J. Physiol. 281 2005 155 161
11. G. Gregoriadis, S. Jain, I. Papaioannou, and P. Laing Improving the therapeutic efficacy of peptides and proteins: a role for polysialic acids Int. J. Pharm. 300 2005 125 130 (Pubitemid 41112174)
12. H. Kim, J. Lee, T.H. Kim, E.S. Lee, K.T. Oh, D.H. Lee, E.S. Park, Y.H. Bae, K.C. Lee, and Y.S. Youn Albumin-coated porous hollow poly(lactic-co- glycolic acid) microparticles bound with palmityl-acylated exendin-4 as a long-acting inhalation delivery system for the treatment of diabetes Pharm. Res. 28 2011 2008 2019
13. H. Kim, H. Park, J. Lee, T.H. Kim, E.S. Lee, K.T. Oh, K.C. Lee, and Y.S. Youn Highly porous large poly(lactic-co-glycolic acid) microspheres adsorbed with palmityl-acylated exendin-4 as a long-acting inhalation system for treating diabetes Biomaterials 32 2011 1685 1693
14. I. Kim, T.H. Kim, K. Ma, E.S. Lee, D. Kim, K.T. Oh, D.H. Lee, K.C. Lee, and Y.S. Youn Synthesis and evaluation of human serum albumin-modified exendin-4 conjugate via heterobifunctional polyethylene glycol linkage with protracted hypoglycemic efficacy Bioconjug. Chem. 21 2010 1513 1519
15. I. Kim, T.H. Kim, K. Ma, E.S. Park, K.T. Oh, E.S. Lee, K.C. Lee, and Y.S. Youn A 4-arm polyethylene glycol derivative conjugated with exendin-4 peptide and palmitylamine having dual-function of size-increase and albumin-binding for long hypoglycemic action Regul. Pept. 167 2011 239 245
16. J-G. Kim, L.L. Baggio, D.P. Bridon, J-P. Castaigne, M.F. Robitaille, L. Jette, C. Benquet, and D.J. Druker Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo Diabetes 52 2003 751 759 (Pubitemid 36323583)
17. U.B. Kompella, and V.H.L. Lee Pharmacokinetics of peptide and protein drugs V.H.L. Lee, Peptide and protein drug delivery 1991 Marcel Dekker New York 391 484
18. F. Kratz Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles J. Control. Release 132 2008 171 183
19. K.C. Lee, S.Y. Chae, T.H. Kim, S. Lee, E.S. Lee, and Y.S. Youn Intrapulmonary potential of polyethylene glycol-modified glucagon-like peptide-1s as a type 2 anti-diabetic agent Regul. Pept. 152 2009 101 107
20. S.H. Lee, S. Lee, Y.S. Youn, D.H. Na, S.Y. Chae, Y. Byun, and K.C. Lee Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1 Bioconjug. Chem. 6 2005 377 382 (Pubitemid 40388214)
21. S. Son, S.Y. Chae, C.W. Kim, Y.G. Choi, S.Y. Jung, S. Lee, and K.C. Lee Preparation and structural, biochemical, and pharmaceutical characterizations of bile acid-modified long-acting exendin-4 derivatives J. Med. Chem. 52 2009 6889 6896
22. C.A. Stoddart, G. Nault, S.A. Galkina, K. Thibaudeau, P. Bakis, N. Bousquet-Gagnon, M. Robitaille, M. Bellomo, V. Paradis, P. Liscourt, A. Lobach, M.E. Rivard, R.G. Ptak, M.K. Mankowski, D. Bridon, and O. Quraishi Albumin-conjugated C34 peptide HIV-1 fusion inhibitor: equipotent to C34 and T-20 in vitro with sustained activity in SCID-hu Thy/Liv mice J. Biol. Chem. 283 2008 34045 34052
23. G.M. Subramanian, M. Fiscella, A. Lamousé-Smith, S. Zeuzem, and J.G. McHutchison Albinterferon alpha-2b: a genetic fusion protein for the treatment of chronic hepatitis C Nat. Biotechnol. 25 2007 1411 1419 (Pubitemid 350233139)
24. M. Szayna, M.E. Doyle, J.A. Betkey, H.W. Holloway, R.G. Spencer, N.H. Greig, and J.M. Egan Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats Endocrinology 141 2000 1936 1941 (Pubitemid 32274340)
25. K. Thibaudeau, R. Léger, X. Huang, M. Robitaille, O. Quraishi, C. Soucy, N. Bousquet-Gagnon, P. van Wyk, V. Paradis, J.-P. Castaigne, and D. Bridon Synthesis and evaluation of insulin-human serum albumin conjugates Bioconjug. Chem. 16 2005 1000 1008 (Pubitemid 41026186)
26. T. Uchio, M. Baudys, F. Liu, S.C. Song, and S.W. Kim Site-specific insulin conjugates with enhanced stability and extended action profile Adv. Drug Deliv. Rev. 35 1999 289 306 (Pubitemid 29073620)
27. G. Xu, D.A. Stoffers, J.F. Habener, and S. Bonner-Weir Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats Diabetes 48 1999 2270 2276 (Pubitemid 30395416)
28. Y.S. Youn, S.Y. Chae, S. Lee, J.E. Jeon, H.G. Shin, and K.C. Lee Evaluation of therapeutic potentials of site-specific PEGylated glucagon-like peptide-1 isomers as a type 2 anti-diabetic treatment: insulinotropic activity, glucose-stabilizing 1capability, and proteolytic stability Biochem. Pharmacol. 73 2007 84 93 (Pubitemid 44853930)